Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.

Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.

Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

Abstract: An oral dosage form of a compound selected from boronic acids which have a neutral thrombin (P1) domain linked to a hydrophobic moiety capable of binding to the thrombin (S2) and (S3) subsites, and salts, prodrugs and prodrug salts of such acids, the dosage form comprising a solid phase formulation comprising the compound and being adapted for reconstitution of the formulation to form a liquid preparation.

Abstract: A method for preventing thrombosis in a setting where rapid onset and/or rapid offset of anticoagulation is required, comprising administering a compound selected from the group consisting of boronic acids which have a neutral thrombin P1 domain linked to a hydrophobic moiety capable of binding to the thrombin S2 and S3 subsites, and pharmaceutically acceptable salts, prodrugs and pharmaceutically acceptable prodrug salts of such acids.

Abstract: A pharmaceutical composition for the suppression of gastric reflux comprises a low viscosity grade sodium alginate, from 0.16 to 2.60 parts by weight of sodium bicarbonate per part by weight of sodium alginate and from 0.10 to 1.04 parts by weight of calcium carbonate per part by weight of sodium alginate. These compositions may be presented in the form of dry powders which can be admixed with water to provide a palatable liquid preparation. However, preferably the compositions are presented in liquid form and a particularly preferred liquid composition comprises an aqueous medium containing 4.0 to 6.0% weight/volume of a low viscosity grade sodium alginate, 2.0 to 3.5% weight/volume of sodium bicarbonate, 1.2 to 2.0% weight/volume of calcium carbonate and 0.6 to 1.2% weight/volume of the sodium salt of an acrylic polymer cross-linked with 1% allyl-sucrose.